Mark Vander Weg: Clinical Trials

3 trials sponsored by Mark Vander Weg, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 unknown, 1 completed. 2 Not applicable, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Not applicable2Completed 1, Unknown 1
Phase 31Unknown 1

Follow Mark Vander Weg: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Treating Smokeless Tobacco Use in Rural Veterans
Tailored behavioral intervention, Behavioral activation for elevated depressive symptoms, Post-cessation weight gain management - Smokeless Tobacco, Nicotine Dependence
Not applicableUnknownMark Vander Weg1232016-12-012019-07-24
Dissemination of a Tailored Tobacco Quitline for Rural Veteran Smokers
Nicotine replacement therapy - Transdermal nicotine patch, Nicotine replacement therapy - Nicotine gum, Nicotine replacement therapy - Nicotine lozenge - Nicotine Dependence, Tobacco Use
Phase 3UnknownMark Vander Weg4112013-07-012017-07-11
Preventing Weight Gain and Controlling Blood Pressure During Smoking Cessation in Hypertensive Smokers
Nicotine Replacement Therapy, Diet - Cardiovascular Diseases, Heart Diseases
Not applicableCompletedMark Vander Weg1392004-09-012024-04-29

Conditions studied

Tobacco Use (2)  ·  Tobacco Use Disorder (2)  ·  Alcohol Drinking (1)  ·  Body Weight (1)  ·  Cardiovascular Diseases (1)  ·  Depression (1)  ·  Heart Diseases (1)  ·  Hypertension (1)  ·  Smoking Cessation (1)  ·  Tobacco Use Cessation (1)

Interventions

Bupropion (2)  ·  Ethanol (2)  ·  Nicotine Chewing Gum (2)  ·  Tobacco Use Cessation Devices (2)  ·  Varenicline (2)  ·  Contraindications (1)  ·  Diet (1)  ·  Health Records, Personal (1)  ·  Nicotine Replacement Therapy (1)

Countries

United States (3)

Top investigators

Mark W. Vander Weg, PhD (2)  ·  Mark W. Vander Weg, Ph.D. (1)

Results publications

PMID 37142273

NIH funding

R01HL072782 (1)